Biotech · Private company
Zenith Epigenetics
Track this companyFree. Adds Zenith Epigenetics to your Dealase workspace and tells you when its record changes.
Clinical trials96 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- EnzalutamidePhase 2 · mCRPCClinicalTrials.gov · fetched Nov 12, 2026
- EnzalutamidePhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- TalazoparibPhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ZEN003694Phase 2 · mCRPCClinicalTrials.gov · fetched Nov 12, 2026
- ZEN003694Phase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- ZEN003694Phase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- The COSMYC Trial (COmbined Suppression of MYC)PHASE2 · RECRUITING · started Aug 19, 2025ClinicalTrials.gov NCT06922318 · fetched Nov 12, 2026
- ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid TumorsPHASE1 · WITHDRAWN · started Jan 23, 2024ClinicalTrials.gov NCT06161493 · fetched Nov 12, 2026
- ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian CancerPHASE2 · RECRUITING · started Apr 21, 2023ClinicalTrials.gov NCT05071937 · fetched Nov 12, 2026
- A Study of ZEN003694 in People With Squamous Cell Lung CancerPHASE2 · RECRUITING · started Nov 1, 2022ClinicalTrials.gov NCT05607108 · fetched Nov 12, 2026
- ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate CancerPHASE2 · RECRUITING · started Sep 8, 2021ClinicalTrials.gov NCT04986423 · fetched Nov 12, 2026
- ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 26, 2021ClinicalTrials.gov NCT04471974 · fetched Nov 12, 2026
- Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 ProtocolPHASE1_PHASE2 · ENROLLING_BY_INVITATION · started Nov 12, 2019ClinicalTrials.gov NCT04145375 · fetched Nov 12, 2026
- A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast CancerPHASE2 · TERMINATED · started Jun 26, 2019ClinicalTrials.gov NCT03901469 · fetched Nov 12, 2026
- A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerPHASE1_PHASE2 · COMPLETED · started Dec 1, 2016ClinicalTrials.gov NCT02711956 · fetched Nov 12, 2026